Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07005882
What this trial is testing

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

Who this might be right for
Breast Cancer PatientsBreast Cancer Early Stage Breast Cancer (Stage 1-3)HR+/HER2- Breast Cancer+1 more
Azienda Ospedaliero-Universitaria Careggi 21
Not applicableNot Yet RecruitingNCT06873191
What this trial is testing

Learn More About Tukysa Once it is Out in the Korean Market

Who this might be right for
HER2-positive Locally Advanced UnresectableMetastatic Breast Cancer
Pfizer 600
Large-scale testing (Phase 3)UnknownNCT05438810
What this trial is testing

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Who this might be right for
Advanced Breast CancerFemale Breast Cancer
Ahon Pharmaceutical Co., Ltd. 312
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07757230
What this trial is testing

A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shenyang Sunshine Pharmaceutical Co., LTD. 87
Testing effectiveness (Phase 2)Ended earlyNCT02774681
What this trial is testing

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

Who this might be right for
Breast Carcinoma Metastatic in the BrainEstrogen Receptor NegativeHER2/Neu Negative+4 more
Northwestern University 12
Testing effectiveness (Phase 2)WithdrawnNCT04351230
What this trial is testing

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8HER2 Positive Breast CarcinomaMetastatic Breast Carcinoma+1 more
Academic and Community Cancer Research United
Testing effectiveness (Phase 2)Study completedNCT01325207
What this trial is testing

Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer

Who this might be right for
Breast Cancer
Northwestern University 34
Testing effectiveness (Phase 2)Active Not RecruitingNCT04544189
What this trial is testing

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Novartis Pharmaceuticals 69
Testing effectiveness (Phase 2)Active Not RecruitingNCT03917082
What this trial is testing

Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer

Who this might be right for
Breast Cancer FemaleHormone Receptor Positive Tumor
British Columbia Cancer Agency 290
Large-scale testing (Phase 3)Study completedNCT02437318
What this trial is testing

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 572
Testing effectiveness (Phase 2)Ended earlyNCT04191382
What this trial is testing

Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer

Who this might be right for
Breast Cancer
Sanofi 105
Large-scale testing (Phase 3)Study completedNCT00553358
What this trial is testing

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 455
Post-approval studies (Phase 4)Ended earlyNCT04031885
What this trial is testing

Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company 4
Testing effectiveness (Phase 2)Looking for participantsNCT06263543
What this trial is testing

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Who this might be right for
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+2 more
Reshma L. Mahtani, D.O. 75
Early research (Phase 1)Study completedNCT01969643
What this trial is testing

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Who this might be right for
HER2 Positive Breast NeoplasmsHormone Receptor Positive Breast NeoplasmsTriple Negative Breast Neoplasms+1 more
Seagen Inc. 290
Large-scale testing (Phase 3)Study completedNCT01772472
What this trial is testing

Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 1,486
Testing effectiveness (Phase 2)Study completedNCT00371345
What this trial is testing

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Who this might be right for
Breast CancerMetastasis
Bristol-Myers Squibb 92
Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Testing effectiveness (Phase 2)Active Not RecruitingNCT02827877
What this trial is testing

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast CarcinomaStage IIIA Breast CancerStage IIIB Breast Cancer+1 more
City of Hope Medical Center 18
Testing effectiveness (Phase 2)Study completedNCT00458237
What this trial is testing

Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Beth Israel Deaconess Medical Center 11
Next Page